From bench to bedside for gene-directed enzyme prodrug therapy of cancer

Anti-Cancer Drugs

Volumn 16, Issue 4, 2005, Pages 349-359

  Dachs, Gabi U ^a   Tupper, Joanna ^b   Tozer, Gillian M ^c  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Cancer; Cytochrome P450; Cytosine deaminase; Herpes simplex virus; Horseradish peroxidase; Hypoxia; Nitroreductase; Pharmacokinetics; Suicide gene therapy; Thymidine kinase

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ANTINEOPLASTIC AGENT; CARBOXYPEPTIDASE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; GANCICLOVIR; HORSERADISH PEROXIDASE; INDOLEACETIC ACID; N [4 [(2 CHLOROETHYL)(2 MESYLOXYETHYL)AMINO]BENZOYL]GLUTAMIC ACID; NITROREDUCTASE; PARACETAMOL; SN 23862; THYMIDINE KINASE; TIRAPAZAMINE; UNCLASSIFIED DRUG;

BYSTANDER EFFECT; CANCER THERAPY; CLINICAL TRIAL; CYTOTOXICITY; DIARRHEA; DOG; ENZYME THERAPY; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE THERAPY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; MAJOR CLINICAL STUDY; METASTASIS; MOUSE; MULTICENTER STUDY; NONHUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SUICIDE GENE; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; ENZYMES; GENE THERAPY; HUMANS; NEOPLASMS; PRODRUGS;

EID: 15944399454     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200504000-00001     Document Type: Review

References (97)

1. Gene therapy clinical trials world wide. J Gene Med www.wiley.co.uk/ genetherapy/clinical.
2. Rosenberg SA, Aebersold P, Cornetta K, et al. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990; 323:570-578.
3. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346:1185-1193.
4. Muul LM, Tuschong LM, Soenen SL, et al. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood 2003; 101:2563-2569.
5. Lehrman S. Virus treatment questioned after gene therapy death. Nature 1999; 401:517-518.
6. Kohn DB, Sadelain M, Glorioso JC. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer 2003; 3:477-488.
7. Huber BE, Richards CA, Krenitsky TA, Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc Natl Acad Sci USA 1991; 88:8039-8043.
8. Elliott G, O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 1997; 88:223-233.
9. Dilber MS, Phelan A, Aints A, et al. Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22. Gene Ther 1999; 6:12-21.
10. Greco O, Dachs GU. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J Cell Physiol 2001; 187: 22-36.
11. Patterson AV, Saunders MP, Greco O. Prodrugs in genetic chemoradiotherapy. Curr Pharm Des 2003; 9:2131-2154,
12. Kuriyama S, Kikukawa M, Masui K, et al. Cancer gene therapy with HSV-tk/GCV system depends on T-cell-mediated immune responses and causes apoptotic death of tumor cells in vivo. Int J Cancer 1999; 83:374-380.
13. Nishida M, Futami S, Morita I, et al. Hypoxia-reoxygenation inhibits gap junctional communication in cultured human umbilical vein endothelial cells. Endothelium 2000; 7:279-286.
14. O'Malley Jr BW, Chen SH, Schwartz MR, et al. Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res 1995; 55:1080-1085.
15. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 1994; 54:6228-6234.
16. Morse GD, Shelton MJ, O'Donnell AM. Comparative pharmacokinetics of antiviral nucleoside analogues. Clin Pharmacokinet 1993; 24:101-123.
17. Sommadossi JP, Bevan R, Ling T, et al. Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. Rev Infect Dis 1988; 10:S507-S514.
18. Floeth FW, Shand N, Bojar H, et al. Local inflammation and devascularization-in vivo mechanisms of the 'bystander effect' in VPC-mediated HSV-Tk/GCV gene therapy for human malignant glioma. Cancer Gene Ther 2001; 8:843-851.
19. Adachi Y, Tamiya T, Ichikawa T, et al. Experimental gene therapy for brain tumors using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene with 5-fluorocytosine. Hum Gene Ther 2000; 11:77-89.
20. Trask TW, Trask RP, Aguilar-Cordova E, et al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther 2000; 1:195-203.
21. Sung MW, Yeh HC, Thung SN, et al. Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial. Mol Ther 2001; 4: 182-191.
22. Singh S, Cunningham C, Buchanan A, Jolly DJ, Nemunaitis J. Toxicity assessment of intratumoral injection of the herpes simplex type I thymidine kinase gene delivered by retrovirus in patients with refractory cancer. Mol Ther 2001; 4:157-160.
23. Miles BJ, Shalev M, Aguilar-Cordova E, et al. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther 2001; 12:1955-1967
24. Alvarez RD, Gomez-Navarro J, Wang M, et al. Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol Ther 2000; 2:524-530.
25. Hasenburg A, Tong XW, Rojas-Martinez A, et al. Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer. Cancer Gene Ther 2000; 7:839-844.
26. Ram Z, Culver KW, Oshiro EM, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 1997; 3:1354-1361.
27. Klatzmann D, Valery CA, Bensimon G, et al. A phase I/II study of herpes simplex virus type 1 thymidine kinase 'suicide' gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther 1998; 9:2595-2604.
28. Sandmair AM, Loimas S, Puranen P, et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 2000; 11:2197-2205.
29. Kubo H, Gardner TA, Wada Y, et al. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther 2003; 14:227-241.
30. Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000; 11:2389-2401.
31. Jacobs A, Tjuvajev JG, Dubrovin M, et al. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res 2001; 61:2983-2995.
32. Satoh T, Teh BS, Timme TL, et al. Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients. Int J Radiat Oncol Biol Phys 2004; 59:562-571.
33. Hasenburg A, Fischer DC, Tong XW, et al. Histologic and immunohistochemical analysis of tissue response to adenovirus-mediated herpes simplex thymidine kinase gene therapy of ovarian cancer. Int J Gynecol Cancer 2002; 12:66-73.
34. Haack K, Linnebacher M, Eisold S, et al. Induction of protective immunity against syngeneic rat cancer cells by expression of the cytosine deaminase suicide gene. Cancer Gene Ther 2000; 7:1357-1364.
35. Trinh QT, Austin EA, Murray DM, et al. Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res 1995; 55:4808-4812.
36. Pierrefite-Carle V, Baque P, Gavelli A, et al. Regression of experimental liver tumor after distant intra-hepatic injection of cytosine deaminase-expressing tumor cells and 5-fluorocytosine treatment. Int J Mol Med 2000; 5: 275-278.
37. Cutler RE, Blair AD, Kelly MR. Flucytosine kinetics in subjects with normal and impaired renal function. Clin Pharmacol Ther 1978; 24:333-342.
38. Fass RJ, Perkins RL. 5-fluorocytosine in the treatment of cryptococcal and candida mycoses. Ann Intern Med 1971; 74:535-539.
39. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of systemic antifungal drugs. Clin Pharmacokinet 1983; 8:17-42.
40. Hamstra DA, Rice DJ, Pu A, et al. Combined radiation and enzyme/prodrug treatment for head and neck cancer in an orthotopic animal model. Radiat Res 1999; 152:499-507
41. Stackhouse MA, Pederson LC, Grizzle WE, et al. Fractionated radiation therapy in combination with adenoviral delivery of the cytosine deaminase gene and 5-fluorocytosine enhances cytotoxic and antitumor effects in human colorectal and cholangiocarcinoma models. Gene Ther 2000; 7:1019-1026.
42. Crystal RG, Hirschowitz E, Lieberman M, et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the E coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum Gene Ther 1997; 8:985-1001.
43. Freytag SO, Khil M, Stricker H, et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 2002; 62:4968-4976.
44. Cunningham C, Nemunaitis J. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001. Hum Gene Ther 2002; 12:1594-1596.
45. Nemunaitis J, Cunningham C, Senzer N, et al. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther 2003; 10:737-744.
46. Bridgewater JA, Springer CJ, Knox RJ, et al. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur J Cancer 1995; 31A:2362-2370.
47. Knox RJ, Boland MP, Friedlos F, et al. The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochem Pharmacol 1988; 37:4671-4677.
48. Knox RJ, Burke PJ, Chen S, Kerr DJ. CB 1954: from the Walker tumor to NQO2 and VDEPT. Curr Pharm Des 2003; 9:2091-2104.
49. Anlezark GM, Melton RG, Sherwood RF, et al. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)-I. Purification and properties of a nitroreductase enzyme from Escherichia coli-a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem Pharmacol 1992; 44:2289-2295.
50. McNeish IA, Green NK, Gilligan MG, et al. Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954. Gene Ther 1998; 5:1061-1069.
51. Bridgewater JA, Knox RJ, Pitts JD, et al. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite. Hum Gene Ther 1997; 8:709-717.
52. Drabek D, Guy J, Craig R, et al. The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954. Gene Ther 1997; 4:93-100.
53. Clark AJ, Iwobi M, Cui W, et al. Selective cell ablation in transgenic mice expression E. coli nitroreductase. Gene Ther 1997; 4:101-110.
54. Chung-Faye G, Palmer D, Anderson D, et al. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. Clin Cancer Res 2001; 7:2662-2668.
55. Hay MP, Gamage SA, Kovacs MS, et al. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine. J Med Chem 2003; 46:169-182.
56. Helsby NA, Ferry DM, Patterson AV, Pullen SM, Wilson WR. 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT. Br J Cancer 2004; 90:1084-1092.
57. Palmer DH, Mautner V, Mirza D, et al. Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J Clin Oncol 2004; 22:1546-1552.
58. Chang TK, Weber GF, Crespi CL, et al. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993; 53:5629-5637.
59. Clarke L, Waxman DJ. Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res 1989; 49:2344-2350.
60. Chen L, Waxman DJ, Chen D, et al. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res 1996; 56:1331-1340.
61. Griffiths L, Binley K, Iqball S, et al. The macrophage - a novel system to deliver gene therapy to pathological hypoxia. Gene Ther 2000; 7: 255-262.
62. Jounaidi Y, Waxman DJ. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. Cancer Res 2000; 60:3761-3769.
63. Pawlik TM, Nakamura H, Mullen JT, et al. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer 2002; 95:1171-1181.
64. Souhami RL, Craft AW, Van der Eijken JW, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 1997; 350:911-917
65. Lohr M, Hoffmeyer A, Kroger J, et al. Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet 2001; 357: 1591-1592.
66. Salmons B, Lohr M, Gunzburg WH. Treatment of inoperable pancreatic carcinoma using a cell-based local chemotherapy: results of a phase I/II clinical trial. J Gastroenterol 2003; 38:78-84.
67. Patterson AV, Barham HM, Chinje EC, et al. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Br J Cancer 1995; 72:1144-1150.
68. Saunders MP, Patterson AV, Chinje EC, et al. NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line. Br J Cancer 2000; 82:651-656.
69. Saunders MP, Jaffar M, Patterson AV, et al. The relative importance of NADPH:cytochrome c (P450) reductase for determining the sensitivity of human tumor cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions. Biochem Pharmacol 2000; 59:993-996.
70. Patterson AV, Saunders MP, Chinje EC, et al. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. Br J Cancer 1997; 76: 1338-1347.
71. Patterson AV, Williams KJ, Cowen RL, et al. Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumors. Gene Ther 2002; 9:946-954.
72. Cowen RL, Williams KJ, Chinje EC, et al. Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure. Cancer Res 2004; 64:1396-1402.
73. Kyle AH, Minchinton AI. Measurement of delivery and metabolism of tirapazamine to tumor tissue using the multilayered cell culture model. Cancer Chemother Pharmacol 1999; 43:213-220.
74. Graham MA, Senan S, Robin Jr H, et al. Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial. Cancer Chemother Pharmacol 1997; 40:1-10.
75. Springer CJ, Antoniw P, Bagshawe KD, et al. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. J Med Chem 1990; 33:677-681.
76. Marais R, Spooner RA, Stribbling SM, et al. A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy. Nat Biotechnol 1997; 15:1373-1377.
77. Stribbling SM, Friedlos F, Martin J, et al. Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect. Hum Gene Ther 2000; 11:285-292.
78. Pedley RB, Sharma SK, Boxer GM, et al. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Cancer Res 1999; 59:3998-4003.
79. Napier MP, Sharma SK, Springer CJ, et al. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Clin Cancer Res 2000; 6:765-772.
80. Kobori K, Sakakibara H, Maruyama K, et al. A rapid method for determining urinary indoleacetic acid concentration and its clinical significance as the tumor-marker in the diagnosis of malignant diseases. J Uoeh 1983; 5: 213-220.
81. Folkes LK, Rossiter S, Wardman P. Reactivity toward thiols and cytotoxicity of 3-methylene-2-oxindoles, cytotoxins from indole-3-acetic acids, on activation by peroxidases. Chem Res Toxicol 2002; 15:877-882.
82. Wardman P. Indole-3-acetic acids and horseradish peroxidase: a new prodrug/enzyme combination for targeted cancer therapy. Curr Pharm Des 2002; 8:1363-1374.
83. Greco O, Folkes LK, Wardman P, et al. Development of a novel enzyme/prodrug combination for gene therapy of cancer: horseradish peroxidase/indole-3-acetic acid. Cancer Gene Ther 2000; 7:1414-1420.
84. Greco O, Rossiter S, Kanthou C, et al. Horseradish peroxidase-mediated gene therapy: choice of prodrugs in oxic and anoxic tumor conditions. Mol Cancer Ther 2001; 1:1-10.
85. Tupper J, Greco O, Tozer GM, Dachs GU. Analysis of the horseradish peroxidase/indole-3-acetic acid combination in a three-dimensional tumor model. Cancer Gene Ther 2004; 11:508-513.
86. 2 system: possible formation of indole acetate cation radical. Biochem Biophys Res Commun 1980; 93:967-973.
87. Folkes LK, Candeias LP, Wardman P. Toward targeted 'oxidation therapy' of cancer: peroxidase-catalysed cytotoxicity of indole-3-acetic acids. Int J Radiat Oncol Biol Phys 1998; 42:917-920.
88. Folkes LK, Wardman P. Oxidative activation of indole-3-acetic acids to cytotoxic species - a potential new role for plant auxins in cancer therapy. Biochem Pharmacol 2001; 61:129-136.
89. Folkes LK, Dennis MF, Stratford MR, et al. Peroxicase-catalyzed effects of indole-3-acetic acid and analogues on lipid membranes, DNA, and mammalian cells in vitro. Biochem Pharmacol 1999; 57: 375-382.
90. Greco O, Dachs GU, Tozer GM, et al. Mechanisms of cytotoxicity induced by horseradish peroxidase/indole-3-acetic acid gene therapy. J Cell Biochem 2002; 87:221-232.
91. Rysanek K, Vitek V. Increased excretion of 5-hydroxy-indole-acetic acid after the administration of 3-indole-acetic acid (heteroauxine). Experimentia 1959; 15:217-218.
92. Mirsky IA, Diengott D. Hypoglycemic action of indole-3-acetic acid by mouth in patients with diabetes mellitus. Proc Soc Exp Biol 1956; 93: 109-110.
93. Tupper J, Tozer GM, Dachs GU. Use of horseradish peroxidase for gene-directed enzyme prodrug therapy with paracetamol. Br J Cancer 2004; 90:1858-1862.
94. Bennett EM, Anand R, Allan PW, et al. Designer gene therapy using an Escherichia coli purine nucleoside phosphorylase/prodrug system. Chem Biol 2003; 10:1173-1181.
95. Gupta A, Miki K, Xu M, Yamamoto N, Moossa AR, Hoffman RM. Combination efficacy of doxorubicin and adenoviral methioninase gene therapy with prodrug selenomethionine. Anticancer Res 2003; 23:1181-1188.
96. Hsu H, Rainov NG, Quinones A, Eling DJ, Sakamoto KM, Spear MA. Combined radiation and cytochrome CYP4B1/4-ipomeanol gene therapy using the EGR1 promoter. Anticancer Res 2003; 23:2723-2728.
97. McCarthy HO, Yakkundi A, McErlane V, et al. Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N. Cancer Gene Ther 2003; 10:40-48.